Oncotelic’s OT-101 meets safety and efficacy goals in Covid-19 trial
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Oncotelic’s OT-101 meets safety and efficacy goals in Covid-19 trial

24 Nov 2021 (Last Updated November 24th, 2021 09:53)

In the trial, overall survival rose by three times for critical patients treated with OT-101 compared to placebo.

Oncotelic’s OT-101 meets safety and efficacy goals in Covid-19 trial
Oncotelic Therapeutics’ OT-101 works by acting on the host protein of respiratory viruses. Credit: NIAID / Flickr.

Oncotelic Therapeutics has reported that its lead drug candidate, OT-101, met the safety and efficacy goals of Phase II C001 clinical trial in individuals with severe Covid-19 who are admitted to the hospital.

An anti-TGF-β ribonucleic acid therapy, OT-101 demonstrated single-agent activity in individuals with relapsed/refractory cancer in various trials.

As part of the immune evasion mechanisms, tumour cells and the SARS-CoV-2 virus produce TGF- β.

As a result, suppressing TGF- β using OT-101 could have an effect on both cancer and Covid-19.

As compared to standard antiviral therapies and vaccines, OT-101 potentially works against several respiratory viruses by acting on the host protein.

The randomised, placebo-controlled, double-blind, multicentre trial evaluated OT-101 in combination with the standard of care (SOC) as against placebo plus SOC in a total of 32 subjects.

SOC comprises dexamethasone, a drug claimed to boost outcomes in individuals with severe Covid-19.

Findings showed that OT-101 met the safety goals of the trial, indicating that the TGF-β inhibitor therapy was safe to use in people with Covid-19, including those with severe/critical disease.

Furthermore, the mortality was 4.5% in the subjects treated with OT-101 compared to 20% in the placebo arm on day seven, meeting the efficacy signals.

On day seven, 89% of the subjects who received OT-101 had more than 96% reduction in viral load as against 67% in the placebo group.

Overall survival rose by three times for critical patients treated with OT-101, reported at 14 days for OT-101 versus four for those who received placebo.

Oncotelic CEO and chairman Dr Vuong Trieu said: “It is gratifying that the TGF-β concept that we put forward has now been validated.

“The data form the basis for further development of OT-101 as a viable treatment for severe respiratory viral infections, including flu and Covid-19.”

In August 2019, Mateon, which formed due to a reverse merger with Oncotelic, took over the computer and artificial intelligence company PointR Data.